|
Nasdaq Level Ii World
News
- Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting
Regulatory News:
nasdaq level ii 21 May 2012 - NASDAQ OMX Agrees to Acquire BWise, a Leading Governance, Risk Management and Compliance (GRC) Software Solution
NEW YORK -- The NASDAQ OMX Group, Inc. today announced that it has agreed to acquire BWise, a global leader in enterprise governance, risk management and compliance (GRC) software. BWise's premium GRC ...
nasdaq level ii 21 May 2012 - StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial
NEWARK, Calif. -- StemCells, Inc. today announced completion of the first planned interim safety review of the Company's Phase I/II spinal cord injury clinical trial, which indicated that the surgery, ...
nasdaq level ii 21 May 2012 - BUSINESS WIRE: Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual ...
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
nasdaq level ii 21 May 2012 - 600 Patients Recruited in Active Biotechs and Ipsens tasquinimod Clinical Phase III Study
Regulatory News: Active Biotech (NASDAQ OMX NORDIC: ...
nasdaq level ii 21 May 2012 - Deutsche Bank Appointed as Depositary Bank for the Sponsored Level II American Depositary Receipt Program of CorpBanca ...
Deutsche Bank today announced its appointment as successor depositary bank for the Level II American Depositary Receipt program of CorpBanca S.A. , headquartered i
nasdaq level ii 21 May 2012 - BUSINESS WIRE: 600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
nasdaq level ii 21 May 2012
|